Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
September 30, 2025 0.00%
June 30, 2025
March 31, 2025 0.00%
December 31, 2024
September 30, 2024
June 30, 2024
March 31, 2024
December 31, 2023 65.84%
September 30, 2023 0.00%
June 30, 2023 -4.35%
March 31, 2023
December 31, 2022 -43.65%
September 30, 2022
June 30, 2022
March 31, 2022
December 31, 2021 -61.60K%
September 30, 2021 63.45%
June 30, 2021 -134.8%
March 31, 2021 -103.5%
December 31, 2020 -76.15%
September 30, 2020 -35.31%
June 30, 2020 53.15%
March 31, 2020 -291.5%
December 31, 2019 -240.6%
September 30, 2019 -253.3%
Date Value
June 30, 2019 -92.35%
March 31, 2019 -364.2%
December 31, 2018 -102.0%
September 30, 2018 -132.1%
June 30, 2018 8.44%
March 31, 2018 -224.8%
December 31, 2017 -30.00%
September 30, 2017 -36.45%
June 30, 2017 -33.25%
March 31, 2017 -32.68%
December 31, 2016 50.88%
September 30, 2016 23.38%
June 30, 2016 34.32%
March 31, 2016 -18.98%
December 31, 2015 -30.17%
September 30, 2015 0.00%
June 30, 2015 0.00%
March 31, 2015 0.00%
December 31, 2014 0.00%
September 30, 2014 0.00%
June 30, 2014 -119.7%
March 31, 2014 -70.53%
December 31, 2013 99.44%
September 30, 2013 0.00%
June 30, 2013 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Omeros Corp. 96.50%
Hyperion DeFi, Inc. --
ANI Pharmaceuticals, Inc. 54.97%
Corcept Therapeutics, Inc. 98.41%
Veru, Inc. --

Gross Profit Margin (Quarterly) Related Metrics